Sepracor hires execs from Novartis, GSK

Share this article:

Sepracor hired four former Novartis and GlaxoSmithKline marketing and sales executives as it firmed up its senior commercial management staff.

The Massachusetts company, whose biggest product is the sleep drug Lunesta, appointed Mark Iwicki EVP and chief commercial officer, a new position. Iwicki joined from Novartis, where he led the cardiovascular business franchise.

Also from Novartis, Sepracor brought in Jay Smith as SVP of sales. At Novartis Smith served as national VP of sales and head of cardiovascular innovations marketing.

The two former GSK executives included Dean Giovanniello, whom Sepracor hired as VP of marketing, and Thomas Hoover, named VP of new products planning. Giovanniello was most recently executive director of marketing for GSK's migraine products, while Hoover served as its therapy area head, business and commercial analysis.

Sepracor said the new hires were part of an effort “to deliver enhanced performance and productivity across our commercial organization.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...

Xtandi duo boosts rep force for pre-chemo push

Xtandi duo boosts rep force for pre-chemo push

With its label extended to the pre-chemo setting, the prostate cancer drug is poised to reach a new group of urologists, and could upend J&J's Zytiga.